Pfiz­er's Xalko­ri fol­low-up, which smoked the old­er drug in 1st-line pa­tients, scores dou­ble win at the FDA

De­spite be­ing the first to mar­ket in ALK-pos­i­tive non-small cell lung can­cer, Pfiz­er’s Xalko­ri lan­guished on the shelf as oth­er com­peti­tors out­paced it. Now, af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.